Turn Biotechnologies completes latest round of funding
Silicon Valley investor Khosla Ventures joins esteemed group of global investors backing Turn
MOUNTAIN VIEW, Calif., April 28, 2021 /PRNewswire/ Turn Biotechnologies, a company developing novel RNA medicines for untreatable age-related conditions, today announced that it has closed its latest round of funding. The company has the support of investors focused on identifying and backing enterprises that have the potential to change the world with their disruptive technologies.
Khosla Ventures, with a history of investing in Black Swan ideas that offer significant upside, became the newest investor in Turn, joining the Shanda Group and Formic Ventures. These firms have stakes in cutting-edge Asian, European and North American companies and
Turn Biotechnologies completa su más reciente ronda de financiamiento prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Turn Biotechnologies Expands the Potential of its mRNA Platform by Licensing Unique Artificial Niche Technology
Niche tech unlocks the power of Turn science for other parts of body
News provided by
Share this article
Share this article
MOUNTAIN VIEW, Calif., Feb. 3, 2021 /PRNewswire/ Turn Biotechnologies, a company developing medicines for currently untreatable age-related conditions, announced that it has acquired the global rights for new artificial niche (AN) technology that can be used to restore muscle stem cells damaged by aging.
The artificial niche replicates the environment of muscle stem cells through enriched media and structural support via engineered muscle fibers (EMFs). This confocal microscopy image shows how EMFs replicate the shape and collagen content (green) of a muscle fiber (myofiber) to tether isolated muscle stem cells (blue). High resolution electron micrographs on right confirm muscle stem cell anchoring. (Source: Turn Biotechnologies)
/PRNewswire/ Turn Biotechnologies, a company developing medicines for currently untreatable age-related conditions, announced that it has acquired the.